Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases.
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Minerva Neurosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NERV's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NERV underperformed the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: NERV underperformed the US Market which returned -14.9% over the past year.
Price Volatility Vs. Market
How volatile is Minerva Neurosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWe're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
1 month ago | Simply Wall StHow Minerva Neurosciences, Inc. (NASDAQ:NERV) Can Impact Your Portfolio Volatility
2 months ago | Simply Wall StShould You Take Comfort From Insider Transactions At Minerva Neurosciences, Inc. (NASDAQ:NERV)?
Is Minerva Neurosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NERV ($5.31) is trading below our estimate of fair value ($179.14)
Significantly Below Fair Value: NERV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NERV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: NERV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NERV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NERV is overvalued based on its PB Ratio (7.5x) compared to the US Biotechs industry average (2.6x).
How is Minerva Neurosciences forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NERV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NERV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NERV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if NERV's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if NERV's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NERV's Return on Equity is forecast to be high in 3 years time
How has Minerva Neurosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NERV is currently unprofitable.
Growing Profit Margin: NERV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NERV is unprofitable, and losses have increased over the past 5 years at a rate of -7.3% per year.
Accelerating Growth: Unable to compare NERV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: NERV has a negative Return on Equity (-259.84%), as it is currently unprofitable.
How is Minerva Neurosciences's financial position?
Financial Position Analysis
Short Term Liabilities: NERV's short term assets ($47.1M) exceed its short term liabilities ($6.6M).
Long Term Liabilities: NERV's short term assets ($47.1M) exceed its long term liabilities ($43.1M).
Debt to Equity History and Analysis
Debt Level: NERV is debt free.
Reducing Debt: NERV has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Inventory Level: NERV has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if NERV's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NERV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NERV has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -10.5% each year.
What is Minerva Neurosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NERV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate NERV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NERV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NERV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NERV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rémy Luthringer (58yo)
Dr. Rémy Luthringer serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Ventures. He ...
CEO Compensation Analysis
Compensation vs Market: Rémy's total compensation ($USD3.91M) is above average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Rémy's compensation has increased whilst the company is unprofitable.
|Executive Chairman & CEO||5.42yrs||US$3.91m||2.45% $5.1m|
|Executive VP||5.92yrs||US$1.53m||0.52% $1.1m|
|Senior VP||1.75yrs||US$2.24m||no data|
|Senior VP & COO||5.75yrs||US$1.49m||0.067% $139.3k|
|Senior VP & Chief Accounting Officer||5.75yrs||US$845.36k||0.039% $80.8k|
|Vice President of Investor Relations & Corporate Communications||4.67yrs||no data||no data|
|Chief Medical Officer||3.33yrs||US$2.84m||no data|
|Senior VP and Head of Research & Development||no data||no data||no data|
Experienced Management: NERV's management team is seasoned and experienced (5 years average tenure).
|Executive Chairman & CEO||5.42yrs||US$3.91m||2.45% $5.1m|
|Lead Independent Director||2.17yrs||US$272.53k||0.067% $138.7k|
|Independent Director||1.75yrs||US$241.15k||0.0026% $5.3k|
|Independent Director||2.33yrs||US$153.13k||0.025% $53.1k|
|Independent Director||4.42yrs||US$149.63k||0.63% $1.3m|
|Independent Director||5.75yrs||US$156.88k||0.0085% $17.7k|
|Independent Director||4.92yrs||US$153.26k||no data|
Experienced Board: NERV's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Minerva Neurosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Minerva Neurosciences, Inc.
- Ticker: NERV
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$208.254m
- Shares outstanding: 39.22m
- Website: https://www.minervaneurosciences.com
Number of Employees
- Minerva Neurosciences, Inc.
- 1601 Trapelo Road
- Suite 286
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NERV||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jul 2014|
|4MN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2014|
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company’s lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. It also offers MIN-117, a compound that has completed Phase IIb clinical trial for the treatment of patients suffering from major depressive disorder (MDD); and seltorexant, which is in Phase IIb clinical trial for treating insomnia and MDD. The company’ preclinical stage product is MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the MIN-117 compound and roluperidone worlwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, NV for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 10:05|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.